|
1
|
The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump.
|
Proc Natl Acad Sci U S A
|
1994
|
2.71
|
|
2
|
Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance.
|
Cancer Res
|
1993
|
1.99
|
|
3
|
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
|
Cancer Res
|
1996
|
1.82
|
|
4
|
Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines.
|
Cancer Res
|
1993
|
1.81
|
|
5
|
HA-966 effects on striatal dopamine metabolism: implications for dopamine compartmentalization.
|
J Pharm Pharmacol
|
1980
|
1.80
|
|
6
|
Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance.
|
Int J Cancer
|
1988
|
1.78
|
|
7
|
Platelet: transporter of vascular endothelial growth factor.
|
Clin Cancer Res
|
1997
|
1.74
|
|
8
|
Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.
|
Cancer Res
|
1999
|
1.72
|
|
9
|
Synthesis of cyclic oligonucleotides by a modified phosphotriester approach.
|
Nucleic Acids Res
|
1988
|
1.52
|
|
10
|
Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule.
|
Ann Oncol
|
1990
|
1.45
|
|
11
|
Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein.
|
Biochemistry
|
1998
|
1.41
|
|
12
|
Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line.
|
Cancer Res
|
1990
|
1.39
|
|
13
|
Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein.
|
Br J Cancer
|
1995
|
1.32
|
|
14
|
Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets.
|
Blood
|
2000
|
1.23
|
|
15
|
Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells.
|
Cancer Res
|
1989
|
1.22
|
|
16
|
Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression.
|
Cancer Res
|
1992
|
1.21
|
|
17
|
ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion.
|
FEBS Lett
|
1995
|
1.19
|
|
18
|
Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors.
|
Am J Pathol
|
1996
|
1.17
|
|
19
|
Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry.
|
Br J Cancer
|
1995
|
1.14
|
|
20
|
Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation.
|
Blood
|
1989
|
1.11
|
|
21
|
Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells.
|
J Natl Cancer Inst
|
1989
|
1.09
|
|
22
|
Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells.
|
Br J Cancer
|
1993
|
1.08
|
|
23
|
Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas.
|
Clin Cancer Res
|
2000
|
1.08
|
|
24
|
Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein.
|
Br J Cancer
|
1991
|
1.05
|
|
25
|
Evidence for daunomycin efflux from multidrug-resistant 2780AD human ovarian carcinoma cells against a concentration gradient.
|
Biochim Biophys Acta
|
1990
|
1.04
|
|
26
|
Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
|
Blood
|
1996
|
1.04
|
|
27
|
Cortisol is transported by the multidrug resistance gene product P-glycoprotein.
|
Br J Cancer
|
1993
|
1.03
|
|
28
|
Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance.
|
Int J Cancer
|
1995
|
1.00
|
|
29
|
Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells.
|
Biochem Pharmacol
|
1994
|
1.00
|
|
30
|
Recycling glycoproteins do not return to the cis-Golgi.
|
J Cell Biol
|
1988
|
0.99
|
|
31
|
The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance.
|
Br J Cancer
|
1990
|
0.97
|
|
32
|
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.
|
Br J Cancer
|
2009
|
0.96
|
|
33
|
Probing daunorubicin accumulation defects in non-P-glycoprotein expressing multidrug-resistant cell lines using digitonin.
|
Int J Cancer
|
1992
|
0.95
|
|
34
|
P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport.
|
Biochem Pharmacol
|
1991
|
0.93
|
|
35
|
Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
|
Mol Pharmacol
|
1998
|
0.91
|
|
36
|
Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer.
|
Ann Oncol
|
2005
|
0.91
|
|
37
|
Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
|
Clin Cancer Res
|
1995
|
0.91
|
|
38
|
Identification of novel drug resistance-associated proteins by a panel of rat monoclonal antibodies.
|
Int J Cancer
|
1997
|
0.91
|
|
39
|
The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification.
|
Cancer Res
|
1995
|
0.89
|
|
40
|
Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and -sensitive cell lines. A comparison with verapamil.
|
Cancer Chemother Pharmacol
|
1987
|
0.89
|
|
41
|
Differential sensitivity of multi-drug-resistant and -sensitive cells to resistance-modifying agents and the relation with reversal of anthracycline resistance.
|
Int J Cancer
|
1990
|
0.87
|
|
42
|
MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs.
|
Int J Cancer
|
1996
|
0.86
|
|
43
|
CD13/Aminopeptidase N overexpression by basic fibroblast growth factor mediates enhanced invasiveness of 1F6 human melanoma cells.
|
Br J Cancer
|
2006
|
0.86
|
|
44
|
Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells.
|
Br J Cancer
|
1993
|
0.84
|
|
45
|
Analysis of human ascites effect on clonogenic growth of human tumor cell lines and NRK-49F cells in soft agar.
|
Int J Cell Cloning
|
1987
|
0.83
|
|
46
|
Daunorubicin efflux against a concentration gradient in non-P-glycoprotein multidrug-resistant lung-cancer cells.
|
Int J Cancer
|
1994
|
0.82
|
|
47
|
Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukaemia.
|
Br J Cancer
|
1992
|
0.82
|
|
48
|
Peptide transport by the multidrug resistance protein MRP1.
|
Cancer Res
|
2001
|
0.82
|
|
49
|
Daunomycin accumulation in resistant tumor cells as a screening model for resistance modifying drugs: role of protein binding.
|
Cancer Lett
|
1987
|
0.81
|
|
50
|
Large populations of non-clonogenic early apoptotic CD34-positive cells are present in frozen-thawed peripheral blood stem cell transplants.
|
Bone Marrow Transplant
|
2001
|
0.81
|
|
51
|
Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein.
|
FEBS Lett
|
1997
|
0.81
|
|
52
|
Differentiation dependent expression of P-glycoprotein in the normal and neoplastic human kidney.
|
Ann Oncol
|
1991
|
0.80
|
|
53
|
Differential effects of acute and subacute HA-966 treatment on storage and release of striatal dopamine.
|
Eur J Pharmacol
|
1979
|
0.80
|
|
54
|
Potent interaction of flavopiridol with MRP1.
|
Br J Cancer
|
1999
|
0.80
|
|
55
|
The effect of glutathione on the ATPase activity of MRP1 in its natural membranes.
|
FEBS Lett
|
2000
|
0.79
|
|
56
|
Alfalfa mosaic virus temperature-sensitive mutants. III. Mutants with a putative defect in cell-to-cell transport.
|
Virology
|
1986
|
0.79
|
|
57
|
AACR special conference in cancer research. Membrane transport in multidrug resistance, development, and disease. American Association for Cancer Research.
|
Ann Oncol
|
1991
|
0.78
|
|
58
|
Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia.
|
Leukemia
|
2001
|
0.78
|
|
59
|
Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis.
|
Leukemia
|
2003
|
0.78
|
|
60
|
Transporter molecules in multidrug resistance.
|
Cytotechnology
|
1996
|
0.78
|
|
61
|
Non-carrier-mediated uptake of the mannosidase I inhibitor 1-deoxymannojirimycin by K562 erythroleukemic cells.
|
J Biol Chem
|
1989
|
0.77
|
|
62
|
Dopamine hypoactivity measured by in vivo voltammetry.
|
Eur J Pharmacol
|
1980
|
0.76
|
|
63
|
P-glycoprotein-independent decrease in drug accumulation by phorbol ester treatment of tumor cells.
|
Biochem Pharmacol
|
1997
|
0.75
|
|
64
|
Drug-transporter proteins in clinical multidrug resistance.
|
Clin Chim Acta
|
1992
|
0.75
|
|
65
|
In vivo voltammetric investigations into the action of HA-966 on central dopaminergic neurons.
|
Brain Res
|
1981
|
0.75
|
|
66
|
Assay of HA-966 in rat plasma by capillary gas-liquid chromatography with nitrogen-selective detection.
|
J Chromatogr
|
1980
|
0.75
|
|
67
|
Incorporation of [125I]-5-iodo-2-thiouracil in cultured hamster, rabbit, and human melanoma cells.
|
Cancer Res
|
1983
|
0.75
|
|
68
|
Potential radiopharmaceuticals for the detection of ocular melanoma. Part I. 5-iodo-2-thiouracil derivatives.
|
Eur J Nucl Med
|
1983
|
0.75
|
|
69
|
Cross-tolerance of dopamine metabolism to baclofen, gamma-butyrolactone and HA-966 in the striatum and olfactory tubercle of the rat.
|
Life Sci
|
1981
|
0.75
|
|
70
|
Re: How does the MRP/GS-X pump export doxorubicin?
|
J Natl Cancer Inst
|
1996
|
0.75
|
|
71
|
Human interferon does not protect cowpea plant cell protoplasts against infection with alfalfa mosaic virus.
|
Virology
|
1985
|
0.75
|
|
72
|
Binding of [3H]flunitrazepam and [3H]spiperone to melanoma cell membrane preparations.
|
Cancer Lett
|
1985
|
0.75
|